Introduction {#s1}
============

Despite reductions in cigarette consumption and adult smoking prevalence in the years following publication of the 1964 Surgeon General\'s Report [@pone.0071379-Centers1], [@pone.0071379-Centers2] and aggressive tobacco control interventions over the past twenty years [@pone.0071379-Farrelly1], lung cancer has remained the leading cause of cancer death among men in the United States since the mid-1950s and among women, since the late 1980s [@pone.0071379-American1]. Lung cancer survival is directly linked to the stage at diagnosis, with five-year probability of survival of 52% for localized disease, 24% for regional disease, and 4% for disease distant metastases [@pone.0071379-American1]. Few cases (15%) of lung cancer are diagnosed at the localized stage when survival is best [@pone.0071379-American1].

This study is the third in a series that applied actuarial mortality and payer cost analytics to the feasibility of early lung cancer detection and treatment. The first study explored the huge mortality differences between early stage and late stage lung cancer that emerge from national cancer registry data [@pone.0071379-National1] and concluded that the difference could not be explained by well-known testing biases, such as lead-time bias [@pone.0071379-Goldberg1]. The second study examined the ability of repeated annual low dose CT (LDCT) screening to detect cancer at an earlier stage in a high risk population using a mortality and screening and treatment cost model for the commercially-insured population [@pone.0071379-Pyenson1]. This paper demonstrated low payer costs for LDCT screening for lung cancer in per member per month (PMPM) terms: \$0.76 PMPM for 2012 dollars compared to \$2.50, \$1.10, and \$0.95 PMPM for Breast, Cervical and Colorectal cancer screening, respectively (2006 dollars). This second study reported that repeated LDCT screenings resulted in a low cost per life-year saved below \$19,000 in the base case and below \$27,000 (2012 USD) in the highest cost scenario, which is lower than current dollar estimates for cervical or breast cancer screening methods currently recommended by the U.S. Preventive Services Task Force [@pone.0071379-Pyenson1].

Since our first study was published, a large randomized controlled trial, the National Lung Screening Trial (NLST), was stopped early when data showed a 20% reduction in lung cancer mortality in the LDCT screening arm compared to the chest x-ray (CXR) arm after a baseline and two follow-up scans, with no significant adverse effects of the screening program [@pone.0071379-Data1]. A recent commentary noted that the 20% mortality reduction seen in the NLST is inherently an underestimate of the lung cancer case-fatality rate and thus, the true mortality reduction is likely greater than 20% [@pone.0071379-Yankelevitz1]. In 2011, the NLST study group published results for the trial in individuals (aged 55--74) at high risk for lung cancer due to smoking history of at least 30 pack-years [@pone.0071379-Aberle1]. LDCT identified a greater proportion of individuals with local disease (stage IA or IB) compared to CXR (63.0% vs. 47.6%) and a lower proportion of individuals with distant disease (stage IIIB or IV; 20.5% vs. 30.5%) [@pone.0071379-Aberle1]. The NLST\'s use of now-dated screening technology, community standard treatment, and only three annual screenings suggests a much higher mortality reduction through current, more precise LDCT technology combined with best practice treatment standards and extension of repeated screening beyond the NLST\'s three annual screens.

Despite the large population-based studies and randomized controlled trials of LDCT screening for lung cancer, there continues to be debate on recommending screening at the population level. A 2012 systematic review of LDCT screening for lung cancer by Bach et al. concluded that screening may benefit individuals at high risk of lung cancer, though the bulk of the conclusions focused on the potential harms of screening due to follow-up investigations, biopsies, and surgical procedures in patients with benign lesions [@pone.0071379-Bach1]. This review formed the basis for clinical recommendations recommending annual LDCT lung cancer screening in a high risk population - those aged 55--74 with a smoking history of 30 pack-years or more who either currently smoke or have quit within the past 15 years [@pone.0071379-National2]. Subsequently, errors in the review discovered by the authors and others have raised concerns about Bach et al.\'s conclusions [@pone.0071379-Yip1].

Given the tremendous potential for improved diagnosis, treatment and survival from lung cancer screening, several studies have been conducted to examine the cost-effectiveness of these programs. Two studies from 2001 simulated the effect of LDCT compared to no screening in a hypothetical cohort aged 60--74 at high risk of lung cancer over a five-year time horizon; both used data from the Early Lung Cancer Action Project (ELCAP) cohort study [@pone.0071379-Henschke1] to inform the distribution of stage at diagnosis in the LDCT group and also used the Surveillance, Epidemiology and End Results (SEER) program [@pone.0071379-National1] for stage at diagnosis in the no screening group [@pone.0071379-Marshall1], [@pone.0071379-Marshall2]. The first study reported the incremental cost-effectiveness of a one-time screening at \$15,274 (1999 USD; \$25,064 in 2012 USD) per life year saved in a high prevalence scenario and up to \$58,183 (1999 USD; \$95,478 in 2012 USD) per life year saved assuming low lung cancer prevalence when accounting for a lead-time bias of one year [@pone.0071379-Marshall1]. The second study extended the model to assess the impact of repeat annual screenings on cost-effectiveness over five years and demonstrated incremental cost-effectiveness of \$61,723 (1999 USD; \$101,287 in 2012 USD) per life year saved and \$50,473 (1999 USD; \$82,826 in 2012 USD) per quality-adjusted life year saved accounting for one-year decrease in the survival benefit [@pone.0071379-Marshall2]. The conclusion of both papers was that LDCT screening for lung cancer appears to be cost-effective in high risk, elderly populations. Two other simulation modeling studies from the U.S. and Australia argue that LDCT screening for lung cancer is unlikely to be cost-effective [@pone.0071379-Mahadevia1], [@pone.0071379-Manser1]. A 2003 simulation modeling study by Mahadevia et al. estimating the incremental cost-effectiveness of annual helical CT screening compared to no screening in hypothetical cohorts of current, quitting and heavy former smokers aged 60 years showed that annual helical CT screening could reach cost-effectiveness if favorable estimates for influential parameters were used simultaneously and argued that this screening modality was unlikely to be cost-effective in a heavy smoking population [@pone.0071379-Mahadevia1]. Similarly, a 2005 Australian study of LDCT screening for lung cancer in a hypothetical cohort of current male smokers aged 60 and above reported that this intervention was unlikely to be cost-effective assuming society\'s willingness to pay \$50,000 per life year saved unless it achieved greater than a 20% reduction in lung cancer mortality [@pone.0071379-Manser1]. These two studies\' negative findings depend on lower effectiveness of screening than demonstrated by the NLST. McMahon et al.\'s results from a patient-level microsimulation study, again using lower effectiveness of screening than NLST, showed that annual screening of current and former smokers aged 50 to 74 years would cost between \$154,000 and \$207,000 (2012 USD) per quality-adjusted life year saved, compared to no screening intervention and assuming background quit rates among current smokers [@pone.0071379-McMahon1]. In this study, lung cancer-specific mortality was reduced by 18% to 25% at 10-year follow-up in the hypothetical cohorts of persons with at least 20 pack-years of smoking history who received smoking cessation counseling and annual CT screenings for lung cancer.

An important distinction in comparing lung cancer screening to other cancer screening is the concentration of lung cancer risk among former or current smokers. Among adults with lung cancer, 21% report being current smokers, 61% former smokers and 18% never smokers [@pone.0071379-Centers3]. By contrast, mammography is recommended for all women within certain ages and colorectal cancer screening is recommended for all men and women within certain ages. This risk concentration for lung cancer reduces the size of the population needing screening and also coincides with focused smoking cessation opportunities. Several studies have identified lung cancer screening as a "teachable moment" to improve smoking cessation in this heavy smoking population [@pone.0071379-Cox1]--[@pone.0071379-Taylor1], possibly via changes to risk perceptions among current and former smokers [@pone.0071379-Park1]. A study from the Early Lung Cancer Action Project showed that 23% of active smokers reported quitting after a baseline CT scan [@pone.0071379-Ostroff1], a more than four-fold increase over the background quit rate in the general population of approximately 4% [@pone.0071379-Burns1]. A recent modeling study bases its estimate of the cost-effectiveness of CT lung cancer screening programs solely on the inclusion of smoking cessation outcomes of its participants [@pone.0071379-McMahon1]. The incorporation of smoking cessation counseling and treatment in lung cancer screening is likely to achieve greater savings in medical costs and reductions in morbidity and mortality than screening alone. It is also likely to appeal to employers and commercial payers given recent estimates of the excess annual healthcare costs of a smoking employee to a private employer [@pone.0071379-Berman1].

The current study builds upon our two previous studies [@pone.0071379-Goldberg1], [@pone.0071379-Pyenson1] and our actuarial model [@pone.0071379-Pyenson1] to estimate the cost per quality-adjusted life year (QALY) saved through LDCT screening, and shows the impact of integrating various smoking cessation programs for screened, current smokers using a commercial payer perspective. The goal of this study is to determine the cost effectiveness of LDCT screening for lung cancer in a hypothetical population of adults aged 50--64 at high risk for lung cancer and to quantify the additional benefits of incorporating smoking cessation interventions in a lung cancer screening program.

Methods {#s2}
=======

Details on the previous model have been published elsewhere [@pone.0071379-Pyenson1]; briefly, the model adopted a commercial payer (actuarial) perspective and quantified costs and effects of lung cancer screening and associated smoking cessation interventions over a 15-year time horizon. Screening costs were established using U.S. Medicare-reimbursement fees (assuming no patient cost sharing) to both screening and follow-up of suspicious nodules, most of which were not cancer. We set the year of analysis in 2012 and assumed all current smokers and half of the former smokers between age 50 and 64 to be eligible for lung cancer screening, with eligibility set as at least 30 pack-years of smoking history. A pack-year is defined as the equivalent of smoking one pack of cigarettes per day for one year. Using data from the 2010 National Health Interview Survey on cigarette smoking status for those aged 45--64 [@pone.0071379-Schiller1], this resulted in approximately 30% of the US population being eligible for lung cancer screening. In our hypothetical cohort, two-thirds of individuals eligible for screening are current smokers and one-third are former smokers. Cancer treatment costs were determined from a large payer database, Truven Marketscan, and included all hospital, physician, ancillary and drug costs eligible for insurer reimbursement. To allow use of actual insurance program cost information available in large commercial claims databases for the costs of cancer treatment, clinical stages IA and IB were modeled as stage A, clinical stages IIA, IIB, and IIIA were modeled as stage B, and clinical stages IIIB and IV as stage C, using a previous published algorithm [@pone.0071379-Pyenson1]. The A, B, C stages correspond approximately to SEER\'s localized, regional, distant categories [@pone.0071379-National3]. All care costs were tabulated, without any attempt to isolate costs not associated with cancer or to attribute any non-medical costs such as lost productivity, and average population medical costs by age and gender were applied to persons without cancer. The model calculated expected future life years through the use of survival probabilities for each age, gender and lung cancer stage (or no lung cancer). All costs were converted to 2012 dollars. The model\'s outputs were the incremental costs (screening and treatment) and quality-adjusted life years saved during the model period and future life-years after the model period comparing 100% screening to 0% screening.

The current study expands the previous model by estimating the QALYs saved by lung cancer screening and treatment, incorporating the impact of smoking cessation interventions on costs, health care costs saved, and QALYs saved, and addressing the impact of lung cancer screening on economic output. As with the earlier model, a 2-year lead time was assumed for all screening-detected cancer and we used the New York ELCAP data to inform our base case. In this model, we estimate the incremental effect of screening or screening plus cessation treatment over no screening. [Table 1](#pone-0071379-t001){ref-type="table"} presents the input parameters of the model described in this section.
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###### Input parameters for lung cancer screening model.

![](pone.0071379.t001){#pone-0071379-t001-1}

  Parameter                                                                                   Base case estimate        Sensitivity analyses                                                           Reference
  -------------------------------------------------------------------------------------- ----------------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------
  **Costs**                                                                                                                                   
  Lung cancer screening                                                                                                                       
  Average annual cost of low dose spiral CT screening for lung cancer                                \$210                   125%, 150%                                                         [@pone.0071379-Pyenson1]
  Lung cancer treatment in first year of diagnosis                                                                                            
  Average cost, Stage A                                                                            \$82,087                     n/a                                                             [@pone.0071379-Pyenson1]
  Average cost, Stage B                                                                            \$132,464                    n/a                                                             [@pone.0071379-Pyenson1]
  Average cost, Stage C                                                                            \$142,750                    n/a                                                             [@pone.0071379-Pyenson1]
  Smoking cessation treatment                                                                                                                 
  Average cost per smoking cessation counseling session                                              \$83                       n/a                                                 Thomson Reuters Marketscan 2010 trended to 2012
  Average cost of generic nicotine replacement therapy per quit attempt                              \$228                      n/a                                                 Thomson Reuters Marketscan 2010 trended to 2012
  Average cost of generic bupropion per quit attempt                                                 \$290                      n/a                                                 Thomson Reuters Marketscan 2010 trended to 2012
  Average cost of varenicline (Chantix) per quit attempt                                             \$379                      n/a                                                 Thomson Reuters Marketscan 2010 trended to 2012
  Average health care costs incurred per quit                                                         \$0                \$12,031, \$12,093    Base case: [@pone.0071379-Hanmer1]--[@pone.0071379-Tobacco1] Sensitivity estimates for light, intensive cessation programs
  **Survival probabilities**                                                                         **%**                                    
  Estimated annual survival                                                                                                                   
  Male, current smoker                                                                               45.7                                                                                     [@pone.0071379-Schoenbaum1]
  Male, ex-smoker                                                                                    63.0                      +/−5%                                                          [@pone.0071379-Schoenbaum1]
  Male, never smoker                                                                                 68.0                                                                                     [@pone.0071379-Schoenbaum1]
  Female, current smoker                                                                             64.6                                                                                     [@pone.0071379-Schoenbaum1]
  Female, ex-smoker                                                                                  69.6                      +/−5%                                                          [@pone.0071379-Schoenbaum1]
  Female, never smoker                                                                               82.8                                                                                     [@pone.0071379-Schoenbaum1]
  Lung cancer survival                                                                                                                        
  Male, Stage A                                                                                   90.4--96.6                                                                                   [@pone.0071379-Goldberg1]
  Male, Stage B                                                                                   71.8--89.9                                                                                   [@pone.0071379-Goldberg1]
  Male, Stage C                                                                                   26.3--73.7                                                                                   [@pone.0071379-Goldberg1]
  Female, Stage A                                                                                 92.1--97.4                                                                                   [@pone.0071379-Goldberg1]
  Female, Stage B                                                                                 72.6--90.9                                                                                   [@pone.0071379-Goldberg1]
  Female, Stage C                                                                                 27.4--76.0                                                                                   [@pone.0071379-Goldberg1]
  **Screening probabilities**                                                                                                                 
  Baseline LDCT scan                                                                                                                          
  Negative result (no nodules present or semi-positive)                                              79.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  *Positive result (nodule\>5 mm)*                                                                  *21.0*                                                                   [@pone.0071379-New1], personal communication with C. Henschke
  *Follow-up scan in 3 months given positive result*                                                *19.0*                                                                   [@pone.0071379-New1], personal communication with C. Henschke
  Repeat scan at 1 year given follow-up scan                                                         99.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Biopsy given follow-up scan                                                                         1.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Surgery given biopsy after follow-up scan                                                          90.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  *Biopsy given positive result*                                                                     *2.0*                                                                   [@pone.0071379-New1], personal communication with C. Henschke
  Repeat scan at 1 year given biopsy                                                                 76.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Surgery given biopsy                                                                               24.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Repeat LDCT scan (annual)                                                                                                                   
  Negative result (no nodules present or semi-positive)                                              93.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  *Positive result (nodule\>5 mm)*                                                                   *7.0*                                                                   [@pone.0071379-New1], personal communication with C. Henschke
  *Antibiotics and follow-up scan within 1 month given positive result*                              *3.0*                                                                   [@pone.0071379-New1], personal communication with C. Henschke
  Repeat scan at 1 year given antibiotics and follow-up scan                                          5.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Additional follow-up scan at 3 months given antibiotics and follow-up scan                         95.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Biopsy given additional follow-up scan                                                              5.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Surgery given biopsy after antibiotics and follow-up scan                                          90.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Biopsy given antibiotics and follow-up scan                                                         1.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Surgery given biopsy after antibiotics and follow-up scan                                          90.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  *Follow-up scan within 6 months given positive result*                                             *4.0*                                                                   [@pone.0071379-New1], personal communication with C. Henschke
  Repeat scan at 1 year given follow-up scan                                                         99.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Biopsy given follow-up scan                                                                         1.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  Surgery given biopsy after follow-up scan                                                          90.0                                                                    [@pone.0071379-New1], personal communication with C. Henschke
  **Lung cancer probabilities**                                                                      **%**                     **%**          
  Status quo                                                                                                                                  
  Stage A                                                                                            17.4                                                                                      [@pone.0071379-National1]
  Stage B                                                                                            14.6                                                                                      [@pone.0071379-National1]
  Stage C                                                                                            68.0                                                                                      [@pone.0071379-National1]
  Lung cancer screening                                                                         New York ELCAP                  NLST          
  Stage A                                                                                            79.3                       63.0                                                 [@pone.0071379-Aberle1], [@pone.0071379-New1]
  Stage B                                                                                            16.2                       16.5                                                 [@pone.0071379-Aberle1], [@pone.0071379-New1]
  Stage C                                                                                             4.5                       20.5                                                 [@pone.0071379-Aberle1], [@pone.0071379-New1]
  **Smoking probabilities, %**                                                                       **%**                                    
  Male, aged 18+, current smoker                                                                     21.2                                                                                      [@pone.0071379-Schiller1]
  Male, aged 18+, ex-smoker                                                                          25.5                                                                                      [@pone.0071379-Schiller1]
  Female, aged 18+, current smoker                                                                   17.5                                                                                      [@pone.0071379-Schiller1]
  Female, aged 18+, ex-smoker                                                                        17.3                                                                                      [@pone.0071379-Schiller1]
  Probability of participation in smoking cessation treatment among current smokers                  19.2                      +/−10%                                                  Calculated from [@pone.0071379-Schiller1]
  Annual reduction in smoking prevalence with increasing age (Background quit rate)                   2.5                                                                              Calculated from [@pone.0071379-Schiller1]
  **Effectiveness of smoking cessation intervention at 12 months**                              **Odds ratio**                                
  Light cessation intervention (behavioral treatment only)                                1.5 (midpoint of 1.3--1.7)                                                                            [@pone.0071379-Abrams1]
  Pharmacological treatment only                                                          2.55 (midpoint of 1.5--3.6)                                                                           [@pone.0071379-Abrams1]
  Combined behavioral and pharmacological treatment, over either intervention alone       1.5 (midpoint of 1.3--1.7)                                                                            [@pone.0071379-Abrams1]
  Intensive cessation intervention (combined behavioral and pharmacological treatment)               3.04                                                                               Calculated from [@pone.0071379-Abrams1]
  **Quality-adjusted life years**                                                             **Utility weight**                              
  Utility for general population, by age                                                                                                      
  Males, aged 50--59                                                                                 0.819                     +/−10%                                                           [@pone.0071379-Hanmer1]
  Males, aged 60--69                                                                                 0.803                     +/−10%                                                           [@pone.0071379-Hanmer1]
  Males, aged 70--79                                                                                 0.770                     +/−10%                                                           [@pone.0071379-Hanmer1]
  Males, aged 80--89                                                                                 0.742                     +/−10%                                                           [@pone.0071379-Hanmer1]
  Females, aged 50--59                                                                               0.788                     +/−10%                                                           [@pone.0071379-Hanmer1]
  Females, aged 60--69                                                                               0.784                     +/−10%                                                           [@pone.0071379-Hanmer1]
  Females, aged 70--79                                                                               0.748                     +/−10%                                                           [@pone.0071379-Hanmer1]
  Females, aged 80--89                                                                               0.700                     +/−10%                                                           [@pone.0071379-Hanmer1]
  Utility weights for lung cancer patients                                                                                                    
  Stage A                                                                                            0.823                     +/−10%                                                           [@pone.0071379-Sturza1]
  Stage B                                                                                            0.772                     +/−10%                                                           [@pone.0071379-Sturza1]
  Stage C                                                                                            0.573                     +/−10%                                                           [@pone.0071379-Sturza1]
  QALYs saved by smoking cessation                                                                                                            
  Males, aged 55--64                                                                                 2.25                                                                                       [@pone.0071379-Javitz1]
  Females, aged 55--64                                                                               2.01                                                                                       [@pone.0071379-Javitz1]

Unless stated, all costs are presented in 2012 dollars.

Cost of lung cancer screening, treatment and smoking cessation programs {#s2a}
-----------------------------------------------------------------------

We used a previous published [@pone.0071379-Pyenson1] estimate of the cost of annual lung cancer screening, which was developed by applying Medicare reimbursement to follow-up decision tree logic published for a large observational study. Costs included all follow-up from suspicious nodules identified in screening; in the first year of screening, 21% of participants required follow-up LDCT scan or biopsy for a positive result (nodules larger than five millimeters in diameter) and in subsequent years, positive results from screening dropped to 7% (see Exhibit 1 and the Appendix in [@pone.0071379-Pyenson1] for detailed decision trees). These values were based on the New York ELCAP [@pone.0071379-New1] and personal communication with the ELCAP lead investigator (Claudia Henschke, December 6, 2010). They are slightly higher than those reported in the New York ELCAP (14% at baseline and 6% at follow-up) [@pone.0071379-New1] and I-ELCAP studies (16% at baseline) [@pone.0071379-Henschke2] and slightly lower than the 27% at baseline reported by the NLST, though NLST defined a positive result as greater than four, rather than five, millimeters in diameter [@pone.0071379-Aberle1]. The original model included one brief anti-smoking counseling session for each person screened, which was priced using a 2012 Medicare reimbursement rate. In the current modeling, we included the cost of alternative types of cessation programs only for smokers and used a typical, commercial reimbursement rate for these programs. We used previously published estimates for the cost of lung cancer treatment for stages A, B and C, which were developed from a large claims database of commercially-insured people. Our model is retrospective in that it assumes that screening started 15 years prior. We used 2012 cost levels throughout our work instead of applying cost levels of prior years, and we did not apply discount factors to account for the time value of money spent in years prior to 2012. Because medical cost inflation has greatly exceeded discount rates during the past 15 years, our 2012 cumulative tabulation would have produced lower costs had we used prior years\' cost levels and multiplied by discount rates to bring costs to 2012 levels.

Screening efficacy and stage shift {#s2b}
----------------------------------

The previous model used data from the New York ELCAP for probability of detecting lung cancers at Stages A, B, and C using LDCT [@pone.0071379-New1]. For this study, we show results for both the New York ELCAP data and recently published data on LDCT detection of lung cancer by stage in the NLST [@pone.0071379-Aberle1], which reported a lower portion of detected early stage lung cancers, presumably because it used only three annual screens and included older four-sensor LDCT equipment. We have not considered costs or effects associated with identified cancers that could be very slow growing or would resolve on their own in line with NLST\'s low estimate of such cases [@pone.0071379-Aberle1].

Probability of survival {#s2c}
-----------------------

The hypothetical cohort in this study was comprised of individuals with a 30 pack-year history of smoking, and the probability of survival for those without lung cancer accounted for gender, age and smoking status (current or former), which were estimated using results from a 1997 paper by Schoenbaum [@pone.0071379-Schoenbaum1]. For the patients with lung cancer, survival probabilities varied by age, gender, and lung cancer stage at diagnosis and were based on SEER [@pone.0071379-Goldberg1]. We assume that current or former smokers with lung cancer have the same probability of survival.

Quality-adjusted life years {#s2d}
---------------------------

Quality adjusted life years were estimated by multiplying the probability that an individual survives to each future year by a utility weight related to age, sex and stage of lung cancer. Utility weights for the general population of males and females aged 50--59 and 60--69 were obtained from a study using the SF-6D and standard gamble technique in a nationally-representative sample [@pone.0071379-Hanmer1]. Among patients diagnosed with lung cancer, stage, age and sex-specific utilities were multiplied by the utility of lung cancer by stage as determined from a meta-analysis of lung cancer utility weights [@pone.0071379-Sturza1]. Patients with screen-detected cancers were assigned QALYs at ages that accounted for a two-year detection lead time. Lung cancer utilities were defined using the standard gamble method for non-metastatic non-small cell lung cancer (NSCLC), mixed/indeterminate NSCLC, and metastatic NSCLC, which we matched to stages A, B, and C, respectively. We multiply the age and sex dependent utility factors by the lung cancer stage specific utility factors. This reflected the lower quality-of-life at each of the three stages of lung cancer relative to the general quality-of-life by age and sex. For lung cancer patients who died during the analytic horizon (before reaching age 65), we assumed that they experienced the quality of life of a stage C lung cancer patient in their last three months of life. Summing the product of utility weights and annual survival probability across all modeled past and future years generated QALYs for the hypothetical cohort for the screening and non-screening scenarios. The difference in total past and future QALYs for the screening scenarios compared to the without screening scenario generated the incremental QALYs due to screening. Similar to costs, we did not discount QALYs saved by lung cancer screening, as we used a retrospective model. Additionally, when looking only at the impact of lung cancer screening, we assumed that smokers and former smokers had the same quality of life.

Cost and Impact of Smoking Cessation Programs {#s2e}
---------------------------------------------

In the previous model [@pone.0071379-Pyenson1], costs for annual smoking cessation counseling were included in the lung cancer screening cost, but the effects of such counseling on life years and health care costs saved were not modeled. The current study models the costs and impact of no additional cessation program, a light program without pharmaceutical treatment, and three intensive programs each with a different pharmaceutical treatment, to be offered to all current smokers in conjunction with the annual screening. In the comparison group receiving no screening, we assume that persons quit at a specified background rate of 2.5% (calculated from [@pone.0071379-Schiller1]) and capture the incremental effect of cessation in the screening arm as the number of additional quits above the background rate. The modeled light cessation program consists of a single counseling session in addition to the LDCT screening. The intensive program involves up to four counseling sessions and 12 weeks of pharmaceutical treatment, as described in the 2008 Clinical Practice Guidelines on *Treating Tobacco Use and Dependence* [@pone.0071379-Tobacco1]. These options were chosen to model a wide range of potential effects of smoking cessation intervention.

Input parameters on the costs and effectiveness of the smoking cessation interventions are presented in [Table 1](#pone-0071379-t001){ref-type="table"} and detailed methods are provided in a technical appendix ([File S1](#pone.0071379.s001){ref-type="supplementary-material"}). These estimates were derived from the 2010 National Health Interview Survey [@pone.0071379-Schiller1], [@pone.0071379-Centers4], a large administrative claims database (Thomson Reuters Marketscan), a meta-analysis of cessation interventions [@pone.0071379-Abrams1], other cost-utility analyses of smoking cessation interventions [@pone.0071379-Javitz1]--[@pone.0071379-Cromwell1], mortality rates in the general population [@pone.0071379-Social1] and in smokers [@pone.0071379-Goldberg1], [@pone.0071379-Schoenbaum1], and studies of the impact of quitting smoking on health care costs [@pone.0071379-Musich1], [@pone.0071379-Solberg1]. QALYs saved by smoking cessation accounted for a 3% discount rate, a 3.5% background quit rate, and a 37% relapse rate [@pone.0071379-Javitz1].

Sensitivity analyses {#s2f}
--------------------

We conducted a range of sensitivity analyses to the test the robustness of our findings, including using NLST rather than ELCAP data on stage-shift as a result of LDCT screening for lung cancer, varying the utility weights used in estimating QALYs by ten percent, and increasing the cost of screening to 125% and 150%. We also present results for four types of smoking cessation interventions in two categories: light and intensive. Further, we examine the inclusion of health care costs incurred among quitters in the cost of the cessation program, as well as a ten percent change in the participation and quit rates of each program and the ex-smoker mortality rate. Because the medical cost component of the CPI tends to understate medical inflation we produced a sensitivity scenario by trending dollar values of other preventive health interventions to 2012 USD at twice the medical CPI.

Results {#s3}
=======

Assuming annual LDCT screenings are given over 15 years to a cohort of high risk adults aged 50--64, the projected cost of lung cancer screening and treatment in the base case averaged \$1.8 billion per year (totaling \$27.8 billion) and yielded 985,284 QALYs over the 15-year period. The resulting cost-utility ratio comparing 100% participation in repeat annual LDCT screenings to no screening was \$28,240 per QALY gained ([Table 2](#pone-0071379-t002){ref-type="table"}). The light smoking cessation intervention consisting of behavioral treatment cost an additional \$1.4 billion and saved an additional 273,566 QALYs. The intensive smoking cessation intervention consisted of combined behavioral and pharmacological treatment. In all scenarios, the QALYs saved by intensive cessation nearly doubled the QALYs saved by LDCT screening alone (930,754 QALYs). The additional costs of the intensive cessation intervention varied by medication: the generic NRT scenario cost \$3.2 billion, the scenario using generic buproprion cost \$4.1 billion and the cost of varenicline (Chantix) was \$5.3 billion. Adding smoking cessation to these annual screenings resulted in increases in both the costs and QALYs saved, reflected in cost-utility ratios ranging from \$16,198 (intensive intervention using generic NRT) to \$23,185 (light intervention).

10.1371/journal.pone.0071379.t002

###### Projected 15-year costs and quality-adjusted life years saved by lung cancer screening and treatment with and without smoking cessation using stage shifts from the NY-ELCAP and NLST in authors\' actuarial model.
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                                                              NY-ELCAP stage shift   NLST stage shift
  ---------------------------------------------------------- ---------------------- ------------------
  **Screening**                                                                     
  Lung cancer screening and treatment costs                     \$27,824,282,242     \$34,054,299,361
  QALYs saved by screening and treatment                            985,284              722,795
  Cost per QALY saved                                               \$28,240             \$47,115
  **Screening + light smoking cessation intervention**                              
  Additional costs for cessation                                \$1,361,556,665      \$1,361,556,665
  Additional QALYs saved by cessation                               273,566              273,566
  Cost per QALY saved                                               \$23,185             \$35,545
  **Screening + intensive smoking cessation intervention**                          
  ***A. NRT generic plus behavioral***                                              
  Additional costs for cessation                                \$3,212,191,737      \$3,212,191,737
  Additional QALYs saved by cessation                               930,754              930,754
  Cost per QALY saved                                               \$16,198             \$22,537
  ***B. Bupropion generic plus behavioral***                                        
  Additional costs for cessation                                \$4,088,822,965      \$4,088,822,965
  Additional QALYs saved by cessation                               930,754              930,754
  Cost per QALY saved                                               \$16,656             \$23,067
  ***C. Chantix plus behavioral***                                                  
  Additional costs for cessation                                \$5,342,861,783      \$5,342,861,783
  Additional QALYs saved by cessation                               930,754              930,754
  Cost per QALY saved                                               \$17,310             \$23,826

NY-ELCAP, New York Early Lung Cancer Action Project; NLST, National Lung Screening Trial; QALY, quality-adjusted life year.

Sensitivity analyses examined the robustness of the results to variations in model parameters. [Table 2](#pone-0071379-t002){ref-type="table"} presents estimates using NLST stage-shift data which resulted in a slightly higher cost-utility ratio of \$47,115 for lung cancer screening alone and a range from \$22,537 per QALY saved (intensive intervention using generic NRT) to \$35,545 per QALY saved (light intervention) when adding a smoking cessation component to screening. One-way sensitivity analyses of the base case ([Table 3](#pone-0071379-t003){ref-type="table"}) showed that lung cancer screening remained cost-effective to changes in the utility weights, a higher percentage of participants diagnosed in Stage A, and increased costs of LDCT screening. Sensitivity analyses of the cessation scenarios incorporated the health care costs incurred by those who quit over the 15-year period, 10% variation in the participation and quit rates of the cessation programs, and 5% variation in the mortality rate of former smokers. In all cases, lung cancer screening plus cessation remained highly cost-effective at less than \$50,000 per QALY saved. Health care costs incurred over the 15-year period by quitting smoking through light cessation intervention were estimated at \$1.5 billion and through the intensive cessation intervention at \$5.3 billion. These costs equate to an average cost of \$802 and \$2,742 per quit attempt for the light and intensive cessation interventions, respectively, or \$12,031 (light) and \$12,093 (intensive) per successful quit.

10.1371/journal.pone.0071379.t003

###### One-way sensitivity analysis of model parameters.
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                                                                                                  Cost/QALY saved  
  ---------------------------------------------------------------------------- ----------------- ----------------- ----------
  **Sensitivity analysis of the base case** [a](#nt103){ref-type="table-fn"}                                       
  Utility weights                                                                   +/−10%           \$22,367       \$36,820
  Participants diagnosed in Stage A                                                  110%            \$21,730          \-
  Cost of screening                                                               125%, 150%         \$36,421       \$44,602
  **Sensitivity analysis of the cessation scenarios**                                                              
  Health care costs incurred among quitters                                                                        
  Light cessation intervention                                                  \$1,548,238,011         \-          \$24,414
  Intensive cessation intervention[b](#nt104){ref-type="table-fn"}              \$5,294,440,356         \-          \$20,073
  Quit rate and participation rate in cessation program                             +/−10%                         
  Light cessation intervention                                                                       \$22,390       \$23,969
  Intensive cessation intervention[b](#nt104){ref-type="table-fn"}                                   \$16,239       \$18,487
  Ex-smoker mortality rate[c](#nt105){ref-type="table-fn"}                           +/−5%                         
  Light cessation intervention                                                                       \$23,589       \$25,293
  Intensive cessation intervention[b](#nt104){ref-type="table-fn"}                                   \$15,437       \$22,042

Base case uses data from the New York ELCAP study.

For sensitivity analyses, the intensive cessation intervention consists of Chantix plus behavioral treatment.

Accounts for health care costs incurred per quit as related to mortality.

Other preventive health interventions {#s3a}
-------------------------------------

We compared the cost per QALY saved of the current LDCT screening protocol to studies of the cost-effectiveness of lung cancer screening and other preventive health interventions, including colon cancer screening [@pone.0071379-Heitman1], cervical cancer screening via Pap test [@pone.0071379-Mandelblatt1], biennial mammography [@pone.0071379-Stout1], type 2 diabetes screening [@pone.0071379-CDC1], annual HIV testing [@pone.0071379-Paltiel1], in-center dialysis [@pone.0071379-Winkelmayer1], and cholesterol-lowering medication [@pone.0071379-Prosser1]. All costs have been trended to 2012 costs using the medical cost component of the CPI. Costs calculated in foreign currency were first converted into U.S. dollars for that year, updated to account for per capita health expenditures in that country compared to the U.S., and then trended using the CPI. [Table 4](#pone-0071379-t004){ref-type="table"} presents the comparison of results from our model to previously-published cost-utility analyses of other preventive health interventions. Colonoscopy every ten years and annual fecal occult blood screening for colorectal cancer in adults aged 50--75 were highly cost-effective interventions, as was cervical cancer screening in women aged 20--65 every three years with the Papanicolaou (Pap) test. The estimated cost-utility of annual LDCT screening for lung cancer was in line with Pap test for cervical cancer and superior to biennial mammography screening for breast cancer. Lung cancer screening was more cost-effective than type 2 diabetes screening in adults, annual HIV testing in a high risk population, in-center dialysis for end stage renal disease, and cholesterol-lowering medication.

10.1371/journal.pone.0071379.t004

###### Comparison of lung cancer screening with LDCT to other preventive health interventions.
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  Intervention                                                                                   Original value        Year           \$/QALY saved (2012 USD)         \$/QALY saved (2012 USD, sensitivity analysis)   Consistent with USPSTF guidelines            Reference
  ------------------------------------------------------------------------------------------ ---------------------- ---------- -------------------------------------- ------------------------------------------------ ----------------------------------- ------------------------------
  **Lung cancer screening with LDCT in high risk population**                                                                                                                                                                                              
  Annual screening over 15 years, aged 50--64                                                  \$28,240--\$47,115    2012 USD            \$28,240--\$47,115                                  \-                                   Under review             
  **Other preventive health interventions**                                                                                                                                                                                                                
  Colonoscopy every 10 years, ages 50--75                                                           \$4,870          2008 CAN                 \$8,552                                     \$9,625                                      Yes                    [@pone.0071379-Heitman1]
  Annual fecal occult blood screening for colorectal cancer, ages 50--75                       \$15,991--\$18,595    2008 CAN   \$28,080--\$32,652\$31,604--\$36,750                        Yes                             [@pone.0071379-Heitman1]       
  Papanicolaou (Pap) test for cervical cancer, every 3 years in women aged 20--65                   \$11,835         2000 USD                 \$18,662                                    \$28,940                                     Yes                  [@pone.0071379-Mandelblatt1]
  Biennial mammography and clinical breast exam in women, aged 50--75 years                         \$34,000         2000 USD                 \$53,611                                    \$83,139                                     Yes                     [@pone.0071379-Stout1]
  Type 2 diabetes screening, ages 25+                                                               \$56,649         1995 USD                \$105,650                                   \$192,741                                     No                       [@pone.0071379-CDC1]
  Annual HIV testing in high risk population                                                       \$100,000         2001 USD                \$150,745                                   \$223,909                                     Yes                    [@pone.0071379-Paltiel1]
  In-center dialysis vs. no renal replacement therapy                                              \$129,200         2000 USD                \$203,724                                   \$315,928                                     Yes                  [@pone.0071379-Winkelmayer1]
  Cholesterol-lowering medication (statin) vs. Step I diet[a](#nt107){ref-type="table-fn"}    \$130,000--\$260,000   1997 USD           \$227,878--\$455,755                        \$391,442--\$782,883                               \-                     [@pone.0071379-Prosser1]

USD, U.S. dollars; CAN, Canadian dollars.

Among men with LDL\> = 160 mg/dL.

Economic impact of lung cancer screening {#s3b}
----------------------------------------

By reducing deaths of individuals during productive years, lung cancer screening is also likely to increase economic output. To provide insight into this issue, we estimated the incremental annual wages due to screening, and the resulting taxes and total economic impact associated with those wages for people under age 65, assuming the current portion of workers by age and gender [@pone.0071379-Bureau1]. Over the fifteen-year period, we estimated \$4.8 billion in wages gained, \$1.7 billion in income taxes gained, and \$10.6 billion in GDP added. Excluding all costs and effects related to smoking cessation, this would mean that for every dollar spent on lung cancer screening, society would recover \$0.38 of its investment. If included in our calculation, this would further reduce the cost per QALY saved.

Discussion {#s4}
==========

Building on our two other studies [@pone.0071379-Goldberg1], [@pone.0071379-Pyenson1], this simulation study finds that repeat annual lung cancer screenings in a high risk cohort of adults aged 50--64 is highly cost-effective at \$28,240 per QALY gained compared to both the currently accepted cost-effectiveness threshold of \$109,000 per QALY gained [@pone.0071379-Braithwaite1], [@pone.0071379-Weinstein1] and the more conservative threshold of \$50,000 per QALY gained. The cost-utility of our lung cancer screening protocol is comparable to colorectal or cervical cancer screening and superior to breast cancer screening which are all are recommended by U.S. Preventive Services Task Force (USPSTF). Lung cancer screening is less costly than other recommended interventions like HIV testing in a high risk population or in-center dialysis for end-stage renal disease.

The range of costs per QALY saved in our study (\$28,240--\$47,115) is approximately 50% lower than some previous estimates [@pone.0071379-Mahadevia1], [@pone.0071379-Manser1] of the cost-effectiveness of lung cancer screening with LDCT. These other studies used assumptions that LDCT was significantly less effective at reducing mortality or detecting early stage lung cancer than demonstrated by either ELCAP or NLST. Another difference between the current study and previous models is our use of a younger cohort with a lower incidence of lung cancer; by diagnosing fewer cases of lung cancer, we would expect our model to yield a similar or less favorable cost-utility ratio compared to those using an older hypothetical cohort.

Even at older ages, the risk of lung cancer mortality among current smokers is substantially reduced by smoking cessation [@pone.0071379-Doll1]. Linking smoking cessation interventions with the annual screening program improved the cost-effectiveness of lung cancer screening between 20% and 45% by increasing the number of QALYs saved. These findings were robust to inclusion of the additional health care costs incurred by quitters living longer than continuing smokers, as well as variation in participation in the cessation interventions, successful cessation, and mortality among quitters.

Our findings emphasize the unprecedented public health potential of lung cancer screening as a medical home for smokers and ex-smokers to motivate cessation and other health behavior change. For example, the addition of coronary artery calcium scores (CACS) measured by LDCT scan to an existing risk prediction model has been shown to improve risk classifications for coronary heart disease [@pone.0071379-Polonsky1]. Estimating CACS and grading emphysema, chronic obstructive pulmonary disease, and lung damage on annual scans could promote personalized medicine and maximize teachable moments. While concerns about radiation exposure associated with the increased use of diagnostic imaging studies seem likely to encourage thoughtful use [@pone.0071379-SmithBindman1], the average effective dose of radiation from annual LDCT screening for lung cancer [@pone.0071379-Aberle2] is likely to be roughly equivalent to exposure from biennial mammography screening for breast cancer [@pone.0071379-Brenner1] over the long term. The utility of a single tool (LDCT screening) to identify risk and promote behavior change across multiple disease processes represents a cost-saving paradigm in preventive health care that could help to reduce the \$96 billion in annual medical costs attributable to smoking [@pone.0071379-Centers5] and have a tremendous benefit in a population at high risk for the top three leading causes of death in the US.

Our model likely overestimates the cost per QALY saved by lung cancer screening in several ways. First, we used 2012 cost levels throughout our work. Our cost projection is a retrospective model, in that we examine results for 2012 if screening had started 15 years ago. Since medical inflation has been much higher than either general inflation or risk free interest (financial discount) rates, had we applied a present value calculation to lower historical costs, our cost per QALY saved would be significantly lower. From a forecast perspective, our assumption is consistent with the view that healthcare spending maintains its current, high portion of GDP and does not further increase or decline. Similarly, estimates of the QALYs gained per quit in our model used a 3% discount rate [@pone.0071379-Javitz1]. Since we adopted a conservative, commercial payer perspective and assumed medical inflation to equal the discount rate, we have not discounted costs. We note that non-discounted costs are a standard practice for health cost projections by the U.S. Congressional Budget Office as well as in the Property-Casualty insurance industry in the U.S. Based on relationships in the paper by Javitz et al., we estimate that not discounting QALYs would reduce the cost per QALY saved through cessation by roughly 50%. Third, our application of SEER mortality to stages A, B and C likely understates the mortality advantages of screen-detected cancers. We used the historical distributions of the traditional stages Ia, Ib, IIa, IIB, IIIa, IIIb and IV when we mapped SEER mortality to stages A, B, and C. However, it seems likely that screen detected cancers will be more heavily weighted toward the earlier traditional stages within each of our categories A, B, and C, especially because of the progress in LDCT scans detecting smaller nodules, which would increase the live-years saved. We also used a higher rate of positive results than reported by the New York ELCAP or I-ELCAP studies at baseline and follow-up screens, which likely overestimates the follow-up costs for false positive results over the study period. Finally, our cumulative cohort methodology captures 15 annual screenings at age 50 but only one screening for age 64. Because the lung cancer incidence increases with age, our approach overweights the ages with the highest cost/benefit ratio relative to a steady state of screening.

Our sensitivity analyses included increasing the price of lung cancer screening by 50% of our estimated cost and using stage-shift data from both the I-ELCAP and NLST studies. Lung cancer screening remained cost-effective in all scenarios. NLST shows a smaller stage shift than the New York ELCAP figures we utilized in our base case and resulted in a lower mortality reduction. The smaller stage shift can be understood by the limits of NLST---only three annual screens and inclusion of older, four-slice LDCT technology. By default, NLST used community standard practice and not a protocol for follow-up (as used in the I-ELCAP), which may account for the lower observed mortality reduction. However, both I-ELCAP and NLST are voluntary programs and could reflect unknown biases. If future recommendations for lung cancer screening would include a protocol for follow-up, the base case of our cost-utility analysis using New York-ELCAP data may better reflect the effectiveness and cost-effectiveness of LDCT screening at the broader population level.

Results from our simulation model indicate that repeat annual LDCT lung cancer screening for adults aged 50--64 with 30+ pack-years of smoking history is highly cost-effective from a commercial payer perspective. Lung cancer screening becomes even more cost-effective when linked with smoking cessation interventions and this study presents cost-utility ratios across a range of programs consisting of a single counseling session up to a full course of combined behavioral and pharmacological treatment. Annual LDCT lung cancer screening in this high risk population remained cost-effective across all sensitivity analyses and we would expect this screening to become more favorable over time with increased identification of early stage cancers in the routine screening pool. The cost-utility ratios estimated in this study were in line with other cancer screening interventions endorsed by the USPSTF and support inclusion of annual LDCT screening for lung cancer in future USPSTF recommendations.
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